• Immuneering posted a Q2 net loss attributable to common stockholders of USD 17.3 million, or USD 0.27 per share, narrowing from USD 14.4 million, or USD 0.40, a year earlier.
• R&D expense rose to USD 14 million from USD 10.5 million year-ago; G&A increased to USD 5 million from USD 4.3 million.
• Cash, cash equivalents, marketable securities totaled USD 182.7 million at June 30, down from USD 217 million at Dec. 31.
• Phase 3 MAPKeeper 301 trial is underway with patients being dosed; over 30 study locations have been posted.
• Maintained outlook for cash runway into 2029; reiterated mid-2028 topline readout timing for MAPKeeper 301.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050730PRIMZONEFULLFEED9803915) on August 05, 2026, and is solely responsible for the information contained therein.